Annual CFO
$50.70 M
+$22.48 M+79.67%
31 December 2022
Summary:
Eagle Pharmaceuticals annual cash flow from operations is currently $50.70 million, with the most recent change of +$22.48 million (+79.67%) on 31 December 2022. During the last 3 years, it has risen by +$1.20 million (+2.43%). EGRX annual CFO is now -13.95% below its all-time high of $58.92 million, reached on 31 December 2017.EGRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$126.00 K
+$33.39 M+99.62%
30 June 2023
Summary:
Eagle Pharmaceuticals quarterly cash flow from operations is currently -$126.00 thousand, with the most recent change of +$33.39 million (+99.62%) on 30 June 2023. EGRX quarterly CFO is now -100.29% below its all-time high of $42.99 million, reached on 30 June 2022.EGRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$9.32 M
-$43.12 M-127.57%
30 June 2023
Summary:
Eagle Pharmaceuticals TTM cash flow from operations is currently -$9.32 million, with the most recent change of -$43.12 million (-127.57%) on 30 June 2023. EGRX TTM CFO is now -109.58% below its all-time high of $97.30 million, reached on 30 September 2019.EGRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EGRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +2.4% | -111.8% | -123.3% |
| 5 y5 years | -3.2% | -101.2% | -109.6% |
EGRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +79.7% | -100.3% | +99.6% | -118.4% | at low |
| 5 y | 5 years | -9.4% | +79.7% | -100.3% | +99.6% | -109.6% | at low |
| alltime | all time | -13.9% | +426.1% | -100.3% | +99.6% | -109.6% | +71.3% |
Eagle Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$126.00 K(-99.6%) | -$9.32 M(-127.6%) |
| Mar 2023 | - | -$33.51 M(-189.2%) | $33.80 M(-33.3%) |
| Dec 2022 | $50.70 M(+79.7%) | $37.56 M(-383.7%) | $50.70 M(+138.9%) |
| Sept 2022 | - | -$13.24 M(-130.8%) | $21.23 M(-40.3%) |
| June 2022 | - | $42.99 M(-358.8%) | $35.53 M(+3044.2%) |
| Mar 2022 | - | -$16.61 M(-305.6%) | $1.13 M(-96.0%) |
| Dec 2021 | $28.22 M(-43.0%) | $8.08 M(+657.4%) | $28.22 M(-29.3%) |
| Sept 2021 | - | $1.07 M(-87.6%) | $39.90 M(-10.3%) |
| June 2021 | - | $8.59 M(-18.0%) | $44.46 M(-21.8%) |
| Mar 2021 | - | $10.48 M(-47.0%) | $56.82 M(+14.8%) |
| Dec 2020 | $49.50 M(-11.6%) | $19.76 M(+251.2%) | $49.50 M(+86.5%) |
| Sept 2020 | - | $5.63 M(-73.1%) | $26.54 M(-15.8%) |
| June 2020 | - | $20.95 M(+563.5%) | $31.52 M(-4.4%) |
| Mar 2020 | - | $3.16 M(-198.7%) | $32.96 M(-41.1%) |
| Dec 2019 | $55.99 M(+6.9%) | -$3.20 M(-130.2%) | $55.99 M(-42.5%) |
| Sept 2019 | - | $10.61 M(-52.6%) | $97.30 M(+7.7%) |
| June 2019 | - | $22.39 M(-14.5%) | $90.37 M(+22.7%) |
| Mar 2019 | - | $26.18 M(-31.3%) | $73.64 M(+40.6%) |
| Dec 2018 | $52.38 M(-11.1%) | $38.11 M(+933.3%) | $52.38 M(+30.3%) |
| Sept 2018 | - | $3.69 M(-34.9%) | $40.20 M(-9.5%) |
| June 2018 | - | $5.67 M(+15.2%) | $44.40 M(-41.8%) |
| Mar 2018 | - | $4.92 M(-81.0%) | $76.28 M(+29.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | $58.92 M(+10.7%) | $25.92 M(+228.7%) | $58.92 M(-18.8%) |
| Sept 2017 | - | $7.89 M(-79.0%) | $72.55 M(-6.8%) |
| June 2017 | - | $37.55 M(-401.9%) | $77.83 M(+106.7%) |
| Mar 2017 | - | -$12.44 M(-131.4%) | $37.66 M(-29.2%) |
| Dec 2016 | $53.21 M(-647.5%) | $39.55 M(+200.4%) | $53.21 M(-1790.7%) |
| Sept 2016 | - | $13.17 M(-601.8%) | -$3.15 M(-86.3%) |
| June 2016 | - | -$2.62 M(-184.4%) | -$22.95 M(-29.3%) |
| Mar 2016 | - | $3.11 M(-118.5%) | -$32.45 M(+233.9%) |
| Dec 2015 | -$9.72 M(-29.8%) | -$16.80 M(+153.2%) | -$9.72 M(+1123.9%) |
| Sept 2015 | - | -$6.63 M(-45.3%) | -$794.00 K(-38.3%) |
| June 2015 | - | -$12.12 M(-146.9%) | -$1.29 M(-120.9%) |
| Mar 2015 | - | $25.84 M(-428.1%) | $6.17 M(-128.4%) |
| Dec 2014 | - | -$7.88 M(+10.5%) | -$21.74 M(+57.1%) |
| Sept 2014 | -$13.84 M(+135.5%) | -$7.13 M(+52.8%) | -$13.84 M(+96.9%) |
| June 2014 | - | -$4.67 M(+125.2%) | -$7.03 M(+37.9%) |
| Mar 2014 | - | -$2.07 M(-9107.0%) | -$5.10 M(+25.9%) |
| Dec 2013 | - | $23.00 K(-107.3%) | -$4.05 M(-31.2%) |
| Sept 2013 | -$5.88 M(-62.2%) | -$315.40 K(-88.5%) | -$5.88 M(+5.7%) |
| June 2013 | - | -$2.73 M(+167.3%) | -$5.56 M(+96.5%) |
| Mar 2013 | - | -$1.02 M(-43.5%) | -$2.83 M(+56.5%) |
| Dec 2012 | - | -$1.81 M | -$1.81 M |
| Sept 2012 | -$15.55 M | - | - |
FAQ
- What is Eagle Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Eagle Pharmaceuticals?
What is Eagle Pharmaceuticals annual cash flow from operations?
The current annual CFO of EGRX is $50.70 M
What is the all time high annual CFO for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual cash flow from operations is $58.92 M
What is Eagle Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of EGRX is -$126.00 K
What is the all time high quarterly CFO for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly cash flow from operations is $42.99 M
What is Eagle Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of EGRX is -$9.32 M
What is the all time high TTM CFO for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high TTM cash flow from operations is $97.30 M